Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points

Current Medical Research and Opinion

Volumn 31, Issue 7, 2015, Pages 1267-1270

  Yabe, Daisuke ^a,b   Kuwata, Hitoshi ^a   Usui, Ryota ^a   Kurose, Takeshi ^a   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Composite end points; Cost effectiveness; GLP 1 receptor agonists; Health related quality of life; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ACUTE PANCREATITIS; ARTICLE; BLOOD BRAIN BARRIER; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREAS ISLET BETA CELL; QUALITY OF LIFE; SODIUM URINE LEVEL; AGONISTS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; QUALITY OF LIFE;

EID: 84934279731     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1045471     Document Type: Article

References (42)

1. Diabetes Atlas 2014 Update. Brussels: International Diabetes Federation, 2014
2. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95
3. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93: 137-88
4. Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014; 16: 492-9
5. Yabe D, Seino Y. Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes. Expet Rev Endocrinol Metabol 2014; 9: 659-70
6. Yabe D, Seino Y, Fukushima K, Seino S. b cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diabetes Rep in press (DOI: 10.1007/s11892-015-0602-9)
7. Yabe D, Kuwata H, Iwasaki M, Seino Y. Why are incretin-based therapies more efficient in East Asians? Perspectives from the pathophysiology of type 2 diabetes and East Asian dietary habits. Eur Med J in press
8. Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 900-9
9. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-23
10. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013; 4: 108-30
11. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Progr Biophys Mol Biol 2011; 107: 248-56
12. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473-88
13. Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-63
14. Ross SA. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr Med Res Opin 2015; 31: 125-35
15. Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of insulin-To-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta cell function. J Diabet Invest 2013; 4: 585-94
16. Meier JJ, Vilsbøll T, Donsmark M, et al. Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass. Diabetologia 2011; 54: S1-S566 (Abstract 896)
17. Kondo Y, Satoh S, Nagakura J, et al. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 2013; 4: 571-5
18. King AB, Montanya E, Pratley RE, et al. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C 58.0%. Endocr Pract 2013; 19: 64-72
19. Langer J, Hunt B, Valentine WJ. Evaluating the short-Term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013; 19: 237-46
20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-42
21. Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of57% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14: 77-82
22. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011; 13: 207-20
23. Gallwitz B, Bohmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-Treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011; 34: 604-6
24. Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with longacting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153-62
25. Raccah D, Gourdy P, Sagnard L, Ceriello A. Lixisenatide as add-on to oral antidiabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes Metab Res Rev 2014; 30: 742-8
26. Hanefeld M, Berria R, Lin J, et al. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. Adv Ther 2014; 31: 861-72
27. Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014; 28: 880-6
28. Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab 2014; 16: 527-36
29. Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol 2012; 11: 142-9
30. Bergenstal RM, Li Y, Porter TK, et al. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c 57%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab 2013; 15: 264-71
31. Grimm M, Li Y, Brunell SC, Blase E. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med 2013; 125: 101-8
32. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus oncedaily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-97
33. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-Treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-57
34. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013; 15: 485-502
35. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; 384: 2228-34
36. Yabe D, Ambos A, Cariou B, et al. Adjunctive lixisenatide treatment improves glycemic control in patients with T2DM irrespective of b-cell function. Diabetes 2014; 64(Suppl 1): A253
37. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs -FDA and EMA assessment. N Engl J Med 2014; 370: 794-7
38. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-17
39. Waser B, Blank A, Karamitopoulou E, et al. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 2014; 28: 391-402
40. Koehler JA, Baggio LL, Yusta B, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 2015; 21: 379-91
41. McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 2014; 86: 241-58
42. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013; 123: 2730-6 Current Medical Research & Opinion Volume 31, Number 7 July 2015 1270 GLP-